End of the Story?
Yesterday, Mylan released a statement saying that the FDA had found its Morgantown plant "in full compliance." Immediately, its share price went up about 5%. A brief sumary can be found here:
I have found no report to this effect from FDA itself. Such regulatory actions are not always easy to access, but it may be worth keeping in mind that the last time the company said the investigation was complete the FDA directly contradicted it.
In the meantime, being "in full compliance" now does not answer the question of the compliance status some months ago, and during the two years production warnings were allegedly overridden. Nor does it answer whether, and how much, defective meds may have gotten into circulation.
Since this story potentially impacts so many people, we will continue to follow it.